| Recruiting | SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer NCT06583070 | Peking University First Hospital | — |
| Completed | Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Re NCT05861778 | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 |
| Recruiting | Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in L NCT06088134 | Mingzhao Xiao | — |
| Completed | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Ge NCT03602079 | Klus Pharma Inc. | Phase 1 / Phase 2 |
| Completed | APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Me NCT02166255 | Wake Forest University Health Sciences | Phase 1 |
| Terminated | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kid NCT02273752 | Emory University | Phase 2 |
| Terminated | Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer NCT01943188 | Stanford University | Phase 1 |
| Completed | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointe NCT01846520 | City of Hope Medical Center | N/A |
| Completed | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery NCT01892930 | Roswell Park Cancer Institute | N/A |
| Completed | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis NCT01806675 | Sanjiv Sam Gambhir | Phase 1 / Phase 2 |
| Completed | Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer NCT01826877 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Terminated | Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer NCT01740154 | Case Comprehensive Cancer Center | N/A |
| Terminated | Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patien NCT01599832 | University of Chicago | N/A |
| Terminated | Clamped or Unclamped Surgery in Treating Patients With Kidney Cancer NCT01547676 | University of Southern California | N/A |
| Completed | Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors NCT01281488 | City of Hope Medical Center | Phase 1 |
| Completed | Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer NCT01157091 | City of Hope Medical Center | Phase 2 |
| Completed | Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies NCT01243359 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanc NCT01198184 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors NCT01155258 | University of Southern California | Phase 1 |
| Terminated | Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does N NCT01582009 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer NCT00684996 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer NCT00408902 | National Cancer Institute (NCI) | Phase 2 |
| Completed | AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery NCT00348699 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer NCT00354250 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer NCT00324740 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer NCT00303862 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer NCT00324870 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer NCT00126659 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer NCT00182702 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Sta NCT00217542 | National Cancer Institute (NCI) | Phase 1 |
| Completed | CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer NCT00112840 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors NCT00112476 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors NCT00655655 | Mayo Clinic | Phase 1 |
| Terminated | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer NCT00098618 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatme NCT00091182 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer NCT00101114 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer NCT00059813 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer NCT00060307 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer NCT00032188 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment NCT00009919 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer NCT00006486 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporin NCT00006251 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transpl NCT00005851 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer NCT00019539 | National Cancer Institute (NCI) | Phase 2 |
| Completed | flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer NCT00019396 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer NCT00040989 | Jonsson Comprehensive Cancer Center | Phase 2 |